CCP succeeded in the EIC Transition call

Czech Centre for Phenogenomics (Institute of Molecular Genetics of the Czech Academy of Sciences), which is a partner in the project TREM2MEDS – Towards the clinical implementation of TREM2 microglia engineering for treating dementia, succeeded as the only applicant from the Czech Republic in the EIC Transitions call.

TREM2MEDS (coordinator: Universita degli Studi di Padova, Italy) — the transplantation of hematopoietic stem/progenitor cells (HSPCs) engineered by lentiviral vectors (LVs) to express robust levels of the Triggering receptor expressed on myeloid cells 2 (TREM2) in their central nervous system (CNS) myeloid/microglial progeny. The restoration of TREM2 function in microglia, by intervening on key mechanisms contributing to neurodegeneration, has the potential to overcome the limited efficacy of current treatments for Alzheimer’s Disease (AD), which only exert symptomatic but not curative effects. The project emerges from the ERC PoC 2022 project TREM2μENGINES, which validated the efficacy of a novel treatment for AD and Nasu-Hakola Disease (NHD) in murine models.